# colorectal cancer - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 72922
- Completion tokens: 44133
- Reasoning tokens: 7409
- Total tokens: 117055
- API requests reported: 6
- Elapsed seconds: 157.462
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: MiniMax

---
<think>Let me analyze this carefully. This is a prognostic transcriptomics analysis for colorectal cancer (CRC) with overall survival (OS) as the endpoint. The user has provided:

1. A list of 100 unique genes with their HR, P values, and FDR
2. Direction counts: 54 risk-associated (HR>1) and 46 protective-associated (HR<1)
3. Background evidence pack including GO/KEGG, STRING, Reactome, and literature records

Let me carefully parse through the input:

**Top risk-associated genes (HR > 1, poor prognosis):**
- INHBB (HR=1.43, FDR=0.001) - strongest risk signal
- SCARA3 (HR=1.38, FDR=0.002)
- DCBLD2 (HR=1.41, FDR=0.009)
- ZEB1-AS1 (HR=1.37, FDR=0.009) - lncRNA
- MIR31HG (HR=1.31, FDR=0.007) - lncRNA
- TPM4 (HR=1.36, FDR=0.009) - actin/muscle
- NPR3 (HR=1.35, FDR=0.016)
- DCBLD2 (HR=1.41)
- LRRC8A (HR=1.38)
- PTPN14 (HR=1.36)
- NIN (HR=1.35)
- AKT3 (HR=1.32)
- NT5E/CD73 (HR=1.31)
- MSLN/mesothelin (HR=1.31)
- GADD45B (HR=1.32)
- SLC2A3/GLUT3 (HR=1.28)
- FGF19 (HR=1.29)
- ITGBL1 (HR=1.30)

**Top protective genes (HR < 1, better prognosis):**
- OGDHL (HR=0.69)
- ATP23 (HR=0.69)
- NDUFA9 (HR=0.69) - mitochondrial
- SLC35G1 (HR=0.69)
- GLYCTK (HR=0.71)
- TAPBPL (HR=0.71)
- CCDC134 (HR=0.71)
- SH3RF2 (HR=0.73)
- MYB (HR=0.77) - interesting, protective!
- CDX2 (HR=0.75) - intestinal differentiation marker
- CDX1 (HR=0.78)
- LGALS4 (HR=0.77) - galectin
- ACSS2 (HR=0.76) - acetate metabolism
- ATP5G1, ATP5B (HR=0.75) - mitochondrial ATP synthase
- CS/citrate synthase (HR=0.75)
- OGDHL (HR=0.69)
- LGALS9 (HR=0.75)
- CASP6 (HR=0.77)
- BCL2L14 (HR=0.76)
- GMNN/geminin (HR=0.76)
- CCL15 (HR=0.75)
- METTL7B (HR=0.76)

Let me organize the biological programs:

**Program 1: EMT / TGF-β signaling / Mesenchymal transition**
- INHBB (Inhibin βB) - TGF-β superfamily, key risk gene (HR=1.43)
- ZEB1-AS1 - antisense to ZEB1, master EMT regulator
- DCBLD2 - discoidin domain receptor tyrosine kinase
- ITGBL1 - integrin beta-like
- MYB - transcription factor (protective here is interesting)
- Possibly MSLN, NIN
- Pathway: Hallmark EMT, TGF-β signaling
- Direction: predominantly risk (poor prognosis)

**Program 2: Mitochondrial bioenergetics / OXPHOS (protective)**
- NDUFA9 (Complex I) - HR=0.69
- ATP5G1, ATP5B (ATP synthase) - HR~0.75
- CS (citrate synthase) - HR=0.75
- OGDHL (2-oxoglutarate dehydrogenase-like) - HR=0.69
- ACSS2 (acetyl-CoA synthetase) - HR=0.76
- TIMM13 - mitochondrial translocase
- COA3, PXMP2, ILVBL
- Pathway: Oxidative phosphorylation, TCA cycle
- Direction: protective (better prognosis)
- This pattern suggests tumors with intact mitochondrial function have better prognosis (Warburg reversal/differentiation)

**Program 3: Intestinal differentiation / Mucosal identity (protective)**
- CDX2 (HR=0.75) - master intestinal transcription factor
- CDX1 (HR=0.78)
- MYB (HR=0.77) - colon crypt regulation
- LGALS4 (HR=0.77) - intestinal galectin
- MYO5B (HR=0.75) - microvilli
- TAPBPL (HR=0.71)
- Pathway: Intestinal epithelial differentiation
- Direction: protective
- Literature: CDX2 inhibits Wnt/β-catenin (PMID 30631044)

**Program 4: Immune microenvironment / Chemokine signaling**
- CCL15 (HR=0.75) - protective here is interesting
- LGALS9 (HR=0.75) - TIM-3 ligand
- NT5E/CD73 (HR=1.31) - adenosine production, immunosuppressive
- DCBLD2 (HR=1.41)
- GADD45B (HR=1.32) - stress response
- MSLN (mesothelin, HR=1.31) - immune checkpoint, CAR-T target (PMID 42363170)
- Pathway: Cytokine signaling, immune regulation
- Note: GO:2000404 Regulation of T Cell Migration was top result

**Program 5: Cell adhesion / Cytoskeleton / Motility**
- TPM4 (tropomyosin, HR=1.36)
- MYO5B (HR=0.75)
- NIN (ninein, HR=1.35)
- PTPN14 (HR=1.36) - tyrosine phosphatase, regulates YAP
- MAP1B (HR=1.33) - microtubule associated
- BACE1 (HR=1.33)
- GJB6 (HR=1.29) - gap junction
- DCBLD2 (HR=1.41)
- ADAMTS18 (HR=1.26) - metalloproteinase
- PPFIBP2 (HR=0.76) - liprin
- ITGBL1 (HR=1.30)
- LRRC4C, NAV3, SCEL
- Pathway: Regulation of phospholipase C activity (top GO)
- STRING: NIN network interactions

Let me now think about key genes for the prognostic signature:

**Top candidates for the signature:**

1. INHBB - top risk gene, TGF-β family, drives CRC malignant phenotypes (PMID 41992239)
2. SCARA3 - scavenger receptor, top risk
3. MIR31HG - lncRNA, top risk
4. ZEB1-AS1 - lncRNA, EMT regulator
5. DCBLD2 - transmembrane receptor, EMT/Wnt
6. TPM4 - actin cytoskeleton
7. NT5E/CD73 - adenosine-mediated immunosuppression (PMID 36480312)
8. MSLN - mesothelin, immunotherapy target (PMID 42363170)
9. FGF19 - growth factor, mitogenic
10. AKT3 - PI3K/AKT signaling

**Protective candidates:**
1. CDX2 - master intestinal TF (PMID 30631044)
2. MYB - colon crypt regulation
3. GLYCTK - glycerate kinase
4. ATP23 - mitochondrial processing
5. OGDHL - 2-OG dehydrogenase-like

**Validation priorities:**

1. INHBB as therapeutic target/biomarker - PMID 41992239 directly supports
2. NT5E/CD73 inhibitor combination with immunotherapy
3. MSLN CAR-T for CRC - PMID 42363170
4. CDX2 maintenance as differentiation therapy
5. Mitochondrial OXPHOS signature - biomarker for prognosis

Let me write the comprehensive response.

Key things to keep in mind:
- The user wants a multidimensional interpretation
- They want programs (not more than 5)
- They want key genes (not more than 10)
- They want validation priorities (not more than 5)
- They want evidence grounding
- They want limitations (not more than 5)
- Independent cohort validation is NOT available
- Several direction conflicts exist (DCBLD2, BCL2L14, LOC101928747|RBMX|SNORD61)

I should not list all 100 genes. The instructions say to synthesize dominant patterns and representative examples.

Let me structure this well. The user wants a very detailed analysis. Let me make sure I cover all 6 requirements thoroughly.

Let me also note the gene context for important ones:
- INHBB: high expression in CRC = poor prognosis (PMID 41992239)
- NT5E: CD73 biomarker for cancer prognosis (PMID 36480312)
- LINC00852: poor prognosis (PMID 34342374) - but here it's protective, conflict
- CDX2: inhibits proliferation via Wnt/β-catenin (PMID 30631044)
- ATP23: prohibitins interaction
- MSLN: CAR-T anti-PD-L1 for CRC (PMID 42363170)

Let me also pay attention to the duplicates and direction conflicts:
- DCBLD2: direction-conflict (some rows protective, some risk)
- BCL2L14: direction-conflict
- LOC101928747|RBMX|SNORD61: direction-conflict

This is fine, the primary display is the representative direction.

OK let me write this out comprehensively.</think>

# Multidimensional Prognostic Interpretation: Colorectal Cancer Overall Survival Transcriptomic Signature

## 1. Overall Biological Interpretation

The 100-gene prognostic signature partitions into two functionally coherent arms that broadly mirror the classical "differentiated-mucosal" vs. "mesenchymal-immunomodulatory" axis of colorectal cancer (CRC) biology. **Risk-associated genes (n=54, HR>1)** are enriched for TGF-β superfamily ligands, EMT transcription/co-factors, cytoskeletal remodeling factors, secreted mitogens (FGF19), and adenosine-generating ectoenzymes — collectively painting a picture of an invasive, stromal-rich, immunologically tolerogenic tumor. **Protective-associated genes (n=46, HR<1)** are dominated by intestinal master transcription factors (CDX1/CDX2), mitochondrial bioenergetic machinery (NDUFA9, ATP5B/G1, CS, OGDHL, ACSS2), and microvillar/differentiation effectors (MYO5B, LGALS4, GLYCTK). Together the signature captures a clinically familiar truth: patients whose tumors retain a differentiated, oxidative-phosphorylation-competent, mucosal-epithelial identity tend to live longer, while tumors that have undergone an EMT-like, mitochondrial-suppressed, TGF-β-driven transition have markedly worse overall survival.

> *Note on evidence hierarchy*: The HR/P/FDR values above are the only direct statistical evidence for this cohort. No independent validation cohort, external replication statistic, or formal enrichment P value is supplied. The GO/KEGG/STRING records and literature calls below are contextual annotation only and do not constitute replication.

---

## 2. Core Biological Programs

### Program 1 — TGF-β / Activin-driven EMT and stromal signaling (Risk)

- **Direction:** Predominantly poor-prognosis.
- **Supporting genes:** **INHBB** (HR=1.43, top risk), **ZEB1-AS1** (HR=1.37), **DCBLD2** (HR=1.41), **ITGBL1** (HR=1.30), **GADD45B** (HR=1.32), **PTPN14** (HR=1.36), **FGF19** (HR=1.29).
- **Standardized pathway:** Hallmark *TGF-β signaling* / Hallmark *EMT*; Reactome *Signaling by TGF-β family members* (R-HSA-170834).
- **Why these genes collectively indicate the program:** INHBB (Inhibin βB / Activin-B) is a direct TGF-β-superfamily ligand; ZEB1-AS1 is the antisense regulator of the canonical EMT transcription factor ZEB1; DCBLD2 is a neuropilin-like transmembrane receptor repeatedly coupled to mesenchymal CRC states; PTPN14 is a non-receptor phosphatase that gates YAP/TAZ and Hippo-driven mesenchymal transcription; FGF19 is a mitogenic signal enriched in mesenchymal/poor-prognosis CRC subsets.
- **Evidence & limits:** **Established evidence** that INHBB overexpression drives malignant phenotypes in CRC cells (Europe PMC PMID 41992239), which is concordant with the cohort's top HR. The remaining members constitute a **supported hypothesis** built on co-occurrence within the same risk arm and on known pathway co-membership, not on direct interaction data. Risk-direction stability is reasonable for INHBB/ZEB1-AS1; DCBLD2 shows a direction conflict across probes in the ledger, which warrants caution.

### Program 2 — Mitochondrial bioenergetics and TCA/OXPHOS competence (Protective)

- **Direction:** Predominantly favorable-prognosis.
- **Supporting genes:** **NDUFA9** (Complex I, HR=0.69), **ATP5G1** and **ATP5B** (F₁Fₒ-ATP synthase, HR≈0.75), **CS** (citrate synthase, HR=0.75), **OGDHL** (HR=0.69), **ACSS2** (HR=0.76), **COA3**, **TIMM13**, **PXMP2**, **NDUFA9**, **DBI**.
- **Standardized pathway:** KEGG *Oxidative phosphorylation* (hsa00190) and *Citrate cycle (TCA cycle)* (hsa00020); Reactome *Respiratory electron transport* (R-HSA-611105); STRING neighborhood anchored by CS–ACSS2–ILVBL and the MT-CO1 neighborhood.
- **Why these genes collectively indicate the program:** All are core components of the mitochondrial matrix/inner-membrane respiratory chain or its substrate-generating enzymes. Their uniform protective direction implies that retained oxidative-phosphorylation capacity, rather than the Warburg-glycolytic state typically emphasized in cancer, marks CRC with better OS — consistent with literature showing OXPHOS-high CRC subtypes are more chemosensitive and differentiated.
- **Evidence & limits:** **Supported hypothesis.** The convergence of multiple independent mitochondrial-complex members on the protective side is internally strong within this dataset, but this is a single-cohort observation with no external replication statistic. ATP23's protective HR (0.69) is consistent with its known role as F₁Fₒ-ATP synthase assembly chaperone (Europe PMC PMID 17135288) but the link to CRC survival is not independently replicated here.

### Program 3 — Intestinal epithelial differentiation and mucosal identity (Protective)

- **Direction:** Favorable-prognosis.
- **Supporting genes:** **CDX2** (HR=0.75), **CDX1** (HR=0.78), **MYB** (HR=0.77), **LGALS4** (HR=0.77), **MYO5B** (HR=0.75), **TAPBPL** (HR=0.71), **CCDC134** (HR=0.71), **PPFIBP2** (HR=0.76), **BCL2L14**, **MCCC2**.
- **Standardized pathway:** GO *intestinal epithelial cell differentiation* (GO:0060575) and *maintenance of gastrointestinal epithelium*; Reactome *Diseases of signal transduction by growth factor receptors*; STRING interactions involving MYB with CREBBP/EP300/KMT2A/GATA2 (transcriptional regulatory axis).
- **Why these genes collectively indicate the program:** CDX2 and CDX1 are the master intestinal homeobox transcription factors; MYB is a colon crypt-progenitor regulator; LGALS4 is an intestinal-epithelium-enriched galectin; MYO5B is essential for apical microvillar trafficking; TAPBPL is an MHC-I chaperone preferentially expressed on gut epithelium. Their concerted protective direction implies that retention of differentiated mucosal identity (and the cellular machinery that maintains it) tracks with longer OS.
- **Evidence & limits:** **Established evidence** for CDX2's tumor-suppressive role via Wnt/β-catenin inhibition (PubMed PMID 30631044). The MYB direction (protective, HR=0.77) is a **supported hypothesis** that is partially counter to literature in other CRC contexts where MYB can be oncogenic; this should be flagged as context-dependent and not yet replicated.

### Program 4 — Immune micro-environment modulation (mixed; mostly risk)

- **Direction:** Mixed, but the highest-impact members skew risk.
- **Supporting genes (risk):** **NT5E/CD73** (HR=1.31), **MSLN/mesothelin** (HR=1.31), **DCBLD2** (HR=1.41), **GJB6** (HR=1.29), **CYP1B1** (HR=1.29). **Protective side:** **CCL15** (HR=0.75), **LGALS9** (HR=0.75, Tim-3 ligand).
- **Standardized pathway:** Reactome *Purinergic signaling* / *Adenosine signaling*; GO *Regulation of T cell migration* (GO:2000404, top retrieved GO term); KEGG *Chemokine signaling*.
- **Why these genes collectively indicate the program:** NT5E generates extracellular adenosine, locally suppressing cytotoxic T cells; MSLN is a tumor-associated antigen whose expression correlates with immunosuppressive microenvironments and is now a CAR-T target (PMID 42363170); CCL15 is a chemokine that can recruit monocytes/lymphocytes; LGALS9 engages Tim-3 to modulate T-cell exhaustion. The recurrent GO term "Regulation of T cell migration" (GO:2000404) from the retrieval supports immune-cell-trafficking involvement, though the direct gene-to-term mapping is not strong in the uploaded statistics.
- **Evidence & limits:** **Established evidence** that NT5E/CD73 is a pan-cancer prognostic biomarker and immunotherapy-response modulator (PubMed PMID 36480312); **supported hypothesis** that MSLN expression in CRC marks an aggressive, immunotolerant subgroup. The protective direction of CCL15/LGALS9 is exploratory and may reflect residual anti-tumor immunity.

### Program 5 — Cytoskeletal remodeling / cell motility / cell-matrix (Risk-leaning)

- **Direction:** Predominantly poor-prognosis.
- **Supporting genes:** **TPM4** (HR=1.36), **NIN** (ninein, HR=1.35), **MAP1B** (HR=1.33), **BACE1** (HR=1.33), **ADAMTS18** (HR=1.26), **SCEL** (HR=1.25), **NAV3**, **LRRC4C**, **LRCH1/LRCH3**, **ITGBL1** (HR=1.30), **GJB6** (HR=1.29).
- **Standardized pathway:** GO *Regulation of phospholipase C activity* (GO:1900274, top retrieved GO); Reactome *Signaling by Rho GTPases*; KEGG *Focal adhesion*; STRING neighborhood for DOCK6/DOCK7/DOCK8–LRCH1/LRCH3, suggesting a motility-regulatory module.
- **Why these genes collectively indicate the program:** TPM4 (tropomyosin-4) and NIN (microtubule-anchoring at the MTOC) directly drive cytoskeletal reorganization; MAP1B is a microtubule-associated protein linked to invasion; ADAMTS18 modulates ECM; BACE1 has emerging roles in cytoskeletal/invasive signaling; ITGBL1 is an integrin-β-like cell-adhesion molecule associated with EMT and metastasis in multiple cancers.
- **Evidence & limits:** **Supported hypothesis.** The PLC-regulation GO term is the strongest retrieved ontology signal and unifies several of these effectors, but no direct protein-protein interaction is documented within the selected-gene STRING edges for most of these pairs. Risk-direction consistency is good (HR 1.25–1.36 across members).

---

## 3. Key Genes and Interaction Modules

### Tier 1 — Lead prognostic candidates (statistically strongest + biologically interpretable)

| Gene | HR / direction | Role in programs | Interaction note |
|---|---|---|---|
| **INHBB** | 1.43 / risk | Lead driver of Program 1 (TGF-β/EMT) | Pathway co-membership with TGF-β superfamily; no direct STRING edge to other selected genes |
| **SCARA3** | 1.38 / risk | Risk arm leader; scavenger-receptor-class A | Indirect/putative relationship to oxidative-stress / stromal remodeling |
| **DCBLD2** | 1.41 / risk (direction conflict across probes) | Programs 1, 4, 5 | Transmembrane receptor; STRING supports physical interaction partners but no direct edge among selected genes |
| **ZEB1-AS1** | 1.37 / risk | Program 1; antisense regulator of ZEB1 | Regulatory interaction with ZEB1 (cis-acting antisense); not physical binding with selected genes |
| **MIR31HG** | 1.31 / risk | lncRNA, Program 1 / Program 5 axis | Co-expression / regulatory with miR-31 family; no direct physical interaction |
| **CDX2** | 0.75 / protective | Program 3 master regulator | Direct transcriptional target gene set (REG4, MUC2 etc. — not in cohort); known transactivation of GSK-3β/Axin2 per PMID 30631044 |
| **OGDHL** | 0.69 / protective | Program 2 (TCA cycle) | Pathway co-membership with 2-OG dehydrogenase complex; not in STRING selected-gene edge list |
| **NT5E (CD73)** | 1.31 / risk | Program 4; adenosine-mediated immunosuppression | Pathway co-membership with ADORA2A/CD39 axis (not in cohort); no direct STRING edge to selected genes |
| **MSLN** | 1.31 / risk | Program 4; tumor antigen, CAR-T target | Pathway co-membership with immunosuppressive tumor microenvironment; no direct edge among selected genes |
| **FGF19** | 1.29 / risk | Program 1 / Program 5; mitogenic | Pathway co-membership with FGFR4-βKlotho signaling; no direct edge |

### Notable interaction module — DOCK/Elmo/LRCH neighborhood (STRING)

- **LRCH1** (HR=1.34, risk) and **LRCH3** (HR=1.34, risk) share STRING-documented associations with **DOCK6, DOCK7, DOCK8** and **LRCH4** (all outside the selected cohort). These represent pathway co-membership and putative co-expression within a Rac/Cdc42 GEF signaling module relevant to Program 5; **not** direct physical interactions between LRCH1 and LRCH3 themselves.

### Interaction module — CS–ACSS2–ILVBL (STRING)

- **CS** (HR=0.75, protective), **ACSS2** (HR=0.76, protective), and **ILVBL** (HR=0.72, protective) form a small STRING-supported neighborhood within Program 2, suggesting their protective effect is not independent but reflects a coherent mitochondrial metabolic module. This is **protein/regulatory network evidence** of co-function, **not** direct physical binding.

> **Evidence-type distinctions:** STRING edges retrieved here reflect curated or experimentally reported physical/complex interactions for proteins like GLYCTK–GRHPR–TKFC (Program 2 enzymes) and MYB–CREBBP–EP300 (Program 3 transcription complex). Co-direction in HR is **co-expression / pathway co-membership**, not direct physical interaction. lncRNA/protein pairs (ZEB1-AS1/ZEB1, MIR31HG/miR-31 targets) are **regulatory interactions**, often cis or indirect, and not necessarily physical.

---

## 4. Validation Priorities

### Priority 1 — INHBB as a CRC prognostic biomarker and candidate therapeutic target
- **Category:** Biomarker / Therapeutic target.
- **Why prioritize:** Top HR (1.43, FDR=0.001) in the cohort; mechanistically interpretable; directly supported by an independent functional study (PMID 41992239) showing INHBB drives malignant CRC phenotypes.
- **Dataset evidence:** Strongest risk signal (rank #1) with sub-0.001 FDR.
- **External evidence:** Concordant functional study; otherwise no replication statistic is provided.
- **Next step:** Validate INHBB protein expression by IHC in a fully independent CRC cohort with annotated OS; assess association with EMT markers (ZEB1, vimentin) and response to standard chemotherapy.
- **Status:** **Supported hypothesis** (functional concordance) trending toward **established evidence** if IHC validation replicates.

### Priority 2 — NT5E/CD73–adenosine axis blockade as an immunotherapy adjunct in CRC
- **Category:** Therapeutic target / Biomarker.
- **Why prioritize:** NT5E is in the risk arm (HR=1.31) with established prognostic and immunomodulatory roles (PMID 36480312); adenosine blockade is an active clinical avenue.
- **Dataset evidence:** Risk direction with FDR<0.04; program-level convergence with Program 4.
- **External evidence:** CD73 is a known druggable ectoenzyme; clinical trials of CD73 inhibitors exist across cancers but CRC-specific benefit is not yet established.
- **Next step:** Evaluate NT5E expression against immune infiltration (CD8⁺ T-cell density, PD-L1) in an independent CRC cohort and test whether CD73-high tumors derive greater benefit from anti-PD-1/PD-L1 ± CD73 inhibitor combinations.
- **Status:** **Supported hypothesis** for prognostic biomarker; **exploratory hypothesis** for therapeutic efficacy in CRC specifically.

### Priority 3 — MSLN as a CAR-T target in CRC
- **Category:** Therapeutic target / Interaction-network hypothesis.
- **Why prioritize:** MSLN is a risk-arm gene (HR=1.31); a recent study (PMID 42363170) describes anti-mesothelin CAR-T cells secreting anti-PD-L1 scFv that are active against patient-derived CRC organoids.
- **Dataset evidence:** Risk direction with FDR<0.05; concordant with mesenchymal/immunotolerant phenotype.
- **External evidence:** Early but high-impact preclinical CRC organoid data; no clinical OS replication statistic in the current dataset.
- **Next step:** Stratify MSLN expression in an independent CRC cohort by CMS subtype and stage; assess whether MSLN-high tumors are enriched for mesenchymal/poor-prognosis subtypes.
- **Status:** **Exploratory hypothesis** with mechanistic plausibility.

### Priority 4 — Mitochondrial OXPHOS score as a protective prognostic biomarker
- **Category:** Biomarker.
- **Why prioritize:** Strongest coherent protective program (Program 2) with multiple converging mitochondrial genes (NDUFA9, ATP5B/G1, CS, OGDHL, ACSS2).
- **Dataset evidence:** Six+ mitochondrial genes with HR 0.69–0.77, all FDR<0.07.
- **External evidence:** Concordant with literature on OXPHOS-high CRC subtypes being chemosensitive and better-outcome; no replication statistic is provided here.
- **Next step:** Build a small OXPHOS gene-set score and test it against TCGA-COAD/READ OS in an independent cohort (would be the first external replication, which is currently absent).
- **Status:** **Supported hypothesis** pending external replication.

### Priority 5 — CDX2-driven differentiation maintenance as a prognostic biomarker
- **Category:** Biomarker / Confounding-or-composition check.
- **Why prioritize:** CDX2 (HR=0.75) and CDX1 (HR=0.78) are the strongest single-gene protective signals in the differentiation program; CDX2 loss is a known feature of undifferentiated/aggressive CRC.
- **Dataset evidence:** Two convergent protective signals within FDR<0.06.
- **External evidence:** Established tumor-suppressor role via Wnt/β-catenin inhibition (PMID 30631044).
- **Next step:** Confirm CDX2 IHC as an independent prognostic variable after adjustment for stage, MSI status, and tumor location in an external cohort; check whether CDX2's protective effect is partly a confounder for tumor differentiation grade.
- **Status:** **Established evidence** for the mechanistic role; **supported hypothesis** for its specific HR magnitude in this cohort.

---

## 5. Evidence Grounding (cross-cutting)

| Claim class | Evidence type | Genuinely independent? |
|---|---|---|
| HR/FDR for each gene | **Direct evidence from input dataset** | Yes (the only direct statistic) |
| INHBB ↔ CRC malignancy | Disease-association + published literature (PMID 41992239) | Partly independent (functional study, not OS replication) |
| CDX2 ↔ Wnt inhibition / prognosis | Published literature (PMID 30631044) | Concordant functional study; no OS replication statistic |
| NT5E ↔ pan-cancer prognosis | Published literature (PMID 36480312) | Meta-level evidence; CRC-specific OS replication not in this dataset |
| MSLN ↔ CAR-T in CRC | Published literature (PMID 42363170) | Preclinical, not OS replication |
| GO/KEGG/Reactome/STRING modules | **Pathway/ontology evidence + network evidence** | These are database-derived; many share underlying curated literature, so they are not fully independent of the literature column |
| Tissue expression (GTEx/HPA) | Expression/tissue-specific evidence | Largely independent of OS literature but not of disease-association records |
| GWAS/ClinVar | Genetic/clinical evidence | Independent of expression-based OS evidence, but largely null for these specific CRC-OS genes in this dataset |
| Drug-target (ChEMBL/ClinicalTrials/OpenTargets) | Therapeutic evidence | Availability of a drug ≠ therapeutic efficacy in CRC OS |

**Conflict flags:** (i) **LINC00852** is protective here (HR=0.74) but was reported as poor-prognosis in NSCLC (PMID 34342374) — context-dependent, not a direct contradiction. (ii) **MYB** is protective (HR=0.77) but is generally considered an oncogenic transcription factor in colon cancer; this is a **conflict between dataset direction and prevailing literature** and should be flagged as **insufficient evidence** to call MYB protective without external replication. (iii) **DCBLD2** and **BCL2L14** show direction conflicts across probes in the ledger, indicating probe-level ambiguity rather than a clean direction.

---

## 6. Limitations and Alternative Explanations

1. **Single-cohort, no external replication.** No independent OS cohort statistic is supplied. All pathway/ontology/literature records used above are contextual, not replication. Conclusion magnitudes (HR) should not be treated as portable estimates.
2. **Tumor purity, stromal content, and cell-composition confounding.** Programs 1 (TGF-β/EMT), 4 (immune), and 5 (cytoskeleton/motility) are exactly the kinds of signals that scale with stromal/immune cell fraction. INHBB, GADD45B, FGF19, NT5E, and CCL15 may partly reflect stromal or immune infiltrate composition. Mitigation: tumor-purity-adjusted expression (ESTIMATE/MCPcounter), or in situ validation (IHC, multiplex IF).
3. **Differentiation-grade confounding for Program 3.** CDX1/CDX2 protective effects likely overlap with histologic grade; partial confounding with tumor differentiation is plausible. Mitigation: stratify by grade and MSI status.
4. **Probe-level direction conflicts and unknown identities.** ~53 duplicated probes/genes are retained in the ledger (e.g., DCBLD2, BCL2L14, NIN, AKT3 each have multiple probe rows); PROBE_* identifiers remain unmapped. The headline HRs are representative rows only — sensitivity to probe selection has not been assessed.
5. **Batch/platform and stage-of-disease effects.** Stage, treatment exposure (surgery, chemotherapy, radiotherapy), age, sex, MSI/CIMP status, and CMS subtype are not stratified in the supplied table. A subset of the HR signal could be driven by these covariates rather than intrinsic tumor biology. Adjustment in multivariate Cox models is the appropriate next step.

---

## Cross-cutting summary

This prognostic signature is biologically coherent rather than a random HR list: the risk arm converges on TGF-β-driven EMT, cytoskeletal/invasive machinery, and adenosine-mediated immunosuppression, while the protective arm converges on retained mitochondrial bioenergetics and intestinal mucosal differentiation. The most actionable leads — **INHBB** (biomarker / target), **NT5E/CD73** (immuno-oncology adjunct), **MSLN** (CAR-T target), **CDX2** (differentiation biomarker), and a composite **OXPHOS score** (prognostic biomarker) — are well-positioned for external validation. Independent-cohort replication of the OS associations is the single most important missing step before any of these can be considered clinically actionable rather than exploratory.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=120, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
